Highlights Formycon AG

Equities

FYB

DE000A1EWVY8

Market Closed - Xetra Other stock markets 11:36:14 2024-04-29 am EDT			5-day change	1st Jan Change
41.6 ^EUR	+4.13%		+8.90%	-26.24%

Apr. 25	Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million	Jan. 30	MT
Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. Announces Health Canada Approves FYB201/Ranopto (Ranibizumab)	Dec. 07	CI
EU Medicines Regulator Accepts Marketing Authorization Application for Formycon's Biosimilar Candidate	23-09-29	MT
Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Formycon, Fresenius to Launch Biosimilar for Johnson & Johnson's Anti-inflammatory Drug by 2025	23-08-07	MT
Formycon Announces Submission of the Biologics License Application for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration	23-06-29	CI
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Formycon AG Provides Earnings Guidance for the Year 2023	23-04-27	CI
Formycon AG Announces Successful Results of Phase I Clinical Trial for Ustekinumab Biosimilar Candidate FYB202 and Concludes Clinical Development	23-04-25	CI
Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit	23-02-02	MT
Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-28	CI
Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)	22-09-19	CI
Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)	22-08-29	CI
Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis	22-08-26	CI
Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study	22-08-16	CI
Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2	22-08-03	CI
Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA	22-06-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Formycon AG

Equities

FYB

DE000A1EWVY8

Highlights

Filters